From a weighing scale to a pole: a comparison of two different dosage strategies in mass treatment of Schistosomiasis haematobium

Per Nordin1*, Gabriele Poggensee2, Sabina Mtweve3 and Ingela Krantz1

1The Skaraborg Institute for Research and Development, Skövde, Sweden; 2Nigerian Field Epidemiology and Laboratory Training Program, Abuja, Nigeria; 3Department of Community Health, Kilimanjaro Christian Medical Centre, Moshi, Tanzania

Background: Clinical schistosomiasis in endemic countries is treated with a single dose of praziquantel per 40 mg/kg body weight. Treating according to weight, in resource-poor settings when thousands of doses are to be administered in mass treatment campaigns, is considered problematic. A calibrated dose-pole based on height was developed and is now used in mass treatment campaigns for determining the doses for schoolchildren. The dose-pole will generate dose errors since every child population contains individuals that are either short or tall for weight. The aim of this study is to explore whether the WHO praziquantel pole is a satisfactory dose instrument for mass treatment of S. haematobium.

Methods: In 1996 and 2002, 1,694 children were surveyed in the Kilimanjaro Region, Tanzania. We compared doses given by weight to doses given by height using descriptive statistics and regression.

Conclusions and interpretation: The WHO dose-pole for praziquantel is based on height of the patient; however, children with the same height will differ in weight. Our study shows that children with the same weight could qualify for up to four different dose levels based on their height. The largest variation of doses based on the WHO dose-pole will be found in children below 20 kg of bodyweight. Using bodyweight and tablet halves as the smallest tablet division unit to determine the doses of praziquantel, one only has to identify every 6th kilogram of bodyweight; the doses will then vary a lot less than when using the WHO dose-pole.

Keywords: praziquantel; dosage; mass treatment; S. haematobium; dose-pole; underdosage; overdosage

Responsible Editor: Nawi Ng, Umeå University, Sweden.

*Correspondence to: Per Nordin, The Skaraborg Institute for Research and Development, Stationsgatan 12, SE-541 30 Skövde, Sweden, Email: per.nordin@skaraborg-institute.se

Schistosomiasis is a neglected tropical disease with at least 200 million infected individuals. It causes damage to internal organs which could lead to serious sequelae in the urinary and gastrointestinal tracts. An estimated 650 million people live in endemic areas (1).

According to WHO recommendations, clinical schistosomiasis in endemic countries should be treated with a single dose of praziquantel per 40 mg/kg body weight (1). This single dose is also recommended in mass treatment campaigns of schoolchildren and adults considered to be at risk. To treat according to body weight in resource-poor settings when thousands of doses are to be administered is considered problematic due to a substantial risk of technical and systematic measurement errors (2). A poor scale would generate severe errors in dosing (3, 4).

A calibrated pole based on height was suggested and developed as an alternative for determining the dose for schoolchildren (1, 4) and is now used in mass treatment programs (5–7). Originally, the dose-pole was designed for children between 110 and 178 cm. Later on, children between 94 and 109 cm as well as those above 178 cm were included (2). The WHO mass treatment recommendations also include selected adults at risk in highly and moderately endemic areas (1). In practice, WHO recommendations mean a dose of the divisible 600 mg praziquantel tablet is to be given per body height category (Table 1).

By definition, this approach will always have in-built errors that could lead to both over- and underestimation of the praziquantel dose; every child population will contain individuals that are either short for weight or tall for weight. The distribution of body weight for each given
height will vary depending on what type of child population is under consideration. Consequently, in every population, there will be some individuals who will get a dose outside the recommendations, even if a dosage interval, allowing a lower and upper limit of 30–60 mg/kg respectively, is introduced. This calibration problem has customarily been handled by adjustments of the intervals based on height, instead of weight, to maximize the number of individuals getting a dose considered as acceptable with regards to both toxicity and efficacy (4).

Underdosing has been brought forward as an important risk factor for the development of resistance (9). Development of resistance and side effects of praziquantel in mass treatment programs of *S. haematobium* are, however, not extensively studied (10).

The aim of this study is to explore in both theory and practice whether the WHO praziquantel pole is a satisfactory dose instrument for mass treatment of *S. haematobium*, or whether some other approach could be more appropriate in order to avoid under- and overdosage.

**Subjects and methods**

**Subjects**

The project ‘Sustainable Prevention of Endemic Schistosomiasis’ (SPES) has surveyed schoolchildren, mainly in standard/class four, from the Kiloe and Kivulini villages of the Kilimanjaro Region in Tanzania since 1996 (11). For each examined child, the age, sex, weight, height and *S. haematobium* egg occurrence were recorded. Weight was measured once by a spring scale, height once by a measuring tape affixed to the wall. These measurements were conducted by the same trained public health nurses throughout the years. Altogether, 1,694 children were surveyed in 1996 or 2002 – 837 (49%) girls and 857 (51%) boys with age ranging from 5 to 18 years. Complete observations regarding age, sex, weight, height and weight were obtained from 1,477 (87%) of these children – 736 (50%) girls and 741 (50%) boys (Table 2), which constitutes the empirical material. The theoretical deliberations are based on the manufacturers’ dosage recommendation, 40 mg/kg.

**Table 1.** Doses of praziquantel in numbers of 600 mg tablets by height in cm according to the WHO dose-pole

| Height (cm) | Number of tablets |
|------------|------------------|
| 94–109     | 1                |
| 110–124    | 1.5              |
| 125–137    | 2                |
| 138–149    | 2.5              |
| 150–159    | 3                |
| 160–178    | 4                |
| >178       | 5                |

Modified after WHO (1).

**Table 2.** Mean values, standard deviations, coefficients of variation, minimum and maximum values for the variables age, weight and height among the 1,477 schoolchildren

| Variable          | Mean | Sd  | CV  | Min. | Max. |
|-------------------|------|-----|-----|------|------|
| Age in years      | 11.0 | 2.82| 25.6| 5    | 18   |
| Weight in kg      | 27.3 | 8.02| 29.4| 14   | 65   |
| Height in cm      | 130.4| 12.88| 9.9 | 99   | 170  |

**Statistical methods and data analysis**

We compared doses given by weight to doses given by height with descriptive statistics [proportions, means standard deviations (Sd), coefficient of variation (CV), range] and linear regression. We examined the differences between the two approaches using a Bland-Altman analysis for equality of measures (12). Ninety-five percent confidence limits are given in square brackets. The level of significance is set at 5%.

**Ethical considerations**

The surveys were approved by the Kilimanjaro Christian Medical Centre/Kilimanjaro Christian Medical University College Ethical Committee and the Regional Medical Officer, Kilimanjaro Region. The school authorities gave their consent after having been informed of the purpose of the surveys. All schoolchildren were invited to participate after informed consent from their parents or guardians had been obtained. All children affected with schistosome infections were treated free of charge with praziquantel [single oral dose of 40 mg/kg b.w. as recommended by WHO (1)].

**Results**

The dose-pole is based on the idea that height can be used instead of weight to determine the dose (4), consequently the extent of variation found in weight should also be found in height. However, these two variables are measured in different units (kg and cm); thus the Sds are not directly comparable. The CV – a statistical measure not bound to any units of measurement – shows that weight varies to a larger extent than height in our study. The observed CV for weight is notably three times larger than the CV for height (Table 2).

**The association between weight and height**

In Fig. 1, the scatter plot shows a slightly J-shaped relationship between weight and height. The variation increases as weight and height increase; many values of height are found for each value of weight.

Nevertheless, the variation in height explains the variation in weight to quite a large extent as expressed in the coefficient of determination ($r^2 = 0.82$). What we see is a good correlation, but not real evidence for applicability when translated to the administration of praziquantel.
When examining agreement of measures, the correlation coefficient is not the only issue to consider (12).

Consequences of the recommendation from the drug manufacturers

When using weight, as recommended by the praziquantel drug manufacturers, deviations in dosages are difficult to avoid, since the tablet is produced as a divisible 600 mg unit. The commonly manufactured praziquantel tablet (Biltricide®) has three parallel scores, which means it can be broken into four segments. To divide the tablet into smaller segments than halves would result in a more precise dose, but is a procedure probably not feasible during mass treatment campaigns (13).

Given that weight could be measured accurately and only tablet halves used as recommended by WHO (1), the maximum deviation in dose could never be more than 300 mg per individual. This may be of little importance for a child of moderate to heavy weight or an adult. Theoretically, however, for a child of low weight, this would mean a departure from the recommendation of 40 mg/kg as illustrated by the trajectories in Fig. 2. On the other hand, the children in our study vary in weight from 14 to 65 kg (Table 1), which means that the actual dose could deviate from the recommended dose by as much as ±7.5 mg/kg for those with the lowest weight to ±2.5 mg/kg for those with the highest weight.

From Fig. 2, it can also be deduced that the weight approach, which is based on division of tablets, will result in a globally valid categorization of individuals into determined weight classes. Furthermore, using tablet halves will generate a weight versus dose relationship as illustrated by the range of weight of the children in this study (Table 3). We thereby arrive at eight levels of the dose, from 600 to 2,700 mg in 300 mg steps.

Comparison between the WHO dose-pole and the manufacturers’ recommendations

How do these two approaches (dose-pole and weight) of administering praziquantel relate to one another given that the relationship in Table 3 is regarded as the ‘gold standard’? The choice of the ‘gold standard’ is motivated by the fact that it conforms more closely to the manufacturers’ recommendations. The scatter plot in Fig. 3 depicts how these two ways of deciding the dose correspond to each other. The data points are presented as circles where the size of the circle represents the number of observations in each point. If the methods were in perfect agreement, the circles in the plot would be

![Fig. 1](image1.png)

Fig. 1. A scatter plot of height in cm and weight in kg for 1,477 schoolchildren with a correlation coefficient (r) of 0.9.

![Fig. 2](image2.png)

Fig. 2. Theoretical deviations in mg/kg according to body weight, illustrated by trajectories, when 40 mg/kg is the target dose and 300 mg tablet halves are used as the smallest dose unit.
Table 3. Praziquantel doses according to weight applied to the weight range of 1,477 schoolchildren when tablet halves are used as the minimum segments

| Weight (kg) | Number of tablets |
|------------|-------------------|
| 12–18      | 1                 |
| 19–26      | 1.5               |
| 27–33      | 2                 |
| 34–41      | 2.5               |
| 42–48      | 3                 |
| 49–56      | 3.5               |
| 57–63      | 4                 |
| 64–71      | 4.5               |

centered on the line of equality \(y = x\). In this study, deviations from the line of equality are evident. Furthermore, there is a systematic difference between the two methods illustrated by the fact that the fitted line has a slope slightly different from the line of equality \(b = 0.87\) and \(p < 0.001\).

Figure 4 shows a Bland-Altman plot for comparison of measures applied using our data. Again, the data points are presented as circles, where the size of the circle represents the number of observations in each point. The mean difference is 0.14 \([0.13; 0.16]\), showing that a systematic difference exists and that the use of the dose-pole mean difference is 0.14 \([0.13; 0.16]\), showing that a systematic difference exists and that the use of the dose-pole

and number of pills by weight on the vertical axis with both the line of equality and the fitted line included.

Fig. 3. Frequency weighted scatter plot with doses in number of pills from the dose-pole on the horizontal axis and number of pills by weight on the vertical axis with both the line of equality and the fitted line included.
A detailed illustration of the problem is given in Fig. 5, where the dose outcomes by the two methods are plotted according to the weight of the children in our study. Essentially, this gives the same message as Table 4, but here we also see the trajectories as in Fig. 2. The trajectories represent the different numbers of tablets according to both methods. The filled circles stand for the weight and tablet halves approach. These trajectories are non-overlapping for weight. The hollow circles represent the dose-pole approach; different children with the same weight will receive different doses simply because their heights differ. In our child population, it would mean that children with the same weight qualify for three different dose levels and sometimes even four (Fig. 6). The dose-pole also appears to give the largest deviations from the target dose in children below 20 kg (Fig. 5).

From Fig. 6, it is evident that a child could be given as much as 1½ tablets too many or too few in comparison to the ‘gold standard’. Translated into number of children, this means that 31 of the 1,477 children in our population would have received either one or more tablets too many (21) or one or more tablets too few (10).

To illustrate that the scale-based method will provide doses with less inherent variation, we show two different scenarios in Fig. 7. Two measurement series are presented, one based on an accurate scale and one based on a scale which produces an overestimate of the weight by 2 kg. The hollow circles show the distribution of doses with an accurate scale using an arbitrary weight range from 5 to 83 kg. As shown before, the distribution of doses is not overlapping and is accurate as well, except for children with a weight below 15 kg. Below this weight the inherent variation starts to show. There is only one situation where

**Fig. 4.** Frequency weighted scatter plot of the differences in doses on the y-axis against the mean values of doses on the x-axis when comparing doses given by the dose-pole and doses using the weight approach. Reference lines included for mean differences as well as the limits of agreement.

**Table 4.** Deviations in mg/kg from the target dose of 40 mg/kg, and number and percentage of children using the WHO dose-pole and the weight approach with tablet halves

| Dose classification | Deviation from target (mg/kg) | Using the dose-pole | Using weight |
|---------------------|------------------------------|---------------------|--------------|
| Higher than target  | 41–45                        | 1                   | 0.1          |
|                     | 36–40                        | 1                   | 0.1          |
|                     | 31–35                        | 1                   | 0.1          |
|                     | 26–30                        |                     |              |
|                     | 21–25                        | 4                   | 0.3          |
|                     | 16–20                        | 44                  | 3.0          |
|                     | 11–15                        | 89                  | 6.0          |
|                     | 6–10                         | 406                 | 27.5         |
|                     | 1–5                          | 508                 | 34.4         |
|                     | 1–5                          | 301                 | 20.4         |
| On target           | 0                            | 53                  | 3.6          |
|                     | 1–5                          | 66                  | 4.5          |
| Lower than target   | 6–10                         | 11–15               | 2            |
|                     | 16–20                        | 2                   | 0.1          |

A detailed illustration of the problem is given in Fig. 5, where the dose outcomes by the two methods are plotted according to the weight of the children in our study. Essentially, this gives the same message as Table 4,
the resulting dose goes slightly below 30 mg/kg, namely, at 12 kg body weight. The reason for this is not due to the scale, of course, but is a simple consequence of the fact that we are assuming tablet halves are the smallest practically possible division. If there was a way to easily and repeatedly divide this tablet into quarters or use a syrup preparation, this problem would cease to exist.

The filled circles represent the situation where the scale consistently overestimates the weight of the person by 2 kg; the effect on the dosage is indeed very moderate. A few cases will now get a slightly higher dose. The lowest dose is 33 mg/kg at a true body weight of 9 kg. The maximal dose of 60 mg/kg can be seen at both 5 and 10 kg true body weight. The dosage now really lies within

Fig. 5. Dose by the dose-pole and dose by weight and tablet halves in mg/kg, all according to bodyweight.

Fig. 6. Histograms of doses given by the dose-pole for each dose given by the weight and halves approach.
Fig. 7. Theoretical distribution of doses (mg/kg) in the case of an accurate scale and when the scale overestimates the weight by 2 kg.

Discussion

We are advocating precision in praziquantel dosage because there is poor knowledge of praziquantel’s side effects in mass treatment of *S. haematobium* contexts and also due to the possible risk for resistance development (9, 10). There is a large age-span in the group of children eligible for mass treatment with praziquantel. Our population consisted of schoolchildren 5–18 years old. In endemic countries, it might be difficult to identify the number of eligible children. The estimated proportion of the population in Tanzania between 5 and 15 years of age is 30%, which means that a little less than 14 million children are eligible for mass treatment of praziquantel (14).

If we focus on the difference expressed as mg/kg and based on our findings only select the number of children which would have been given doses with deviations from the target of more than 15 mg/kg, then approximately

Table 5. Theoretically determined doses according to weight using tablet halves as the standard minimum dose fraction based on the weight of the child and with a dose never below 40 mg/kg

| Weight (kg) | Number of tablets |
|------------|-------------------|
| 12–18      | 1                 |
| 19–26      | 1.5               |
| 27–33      | 2                 |
| 34–41      | 2.5               |
| 42–48      | 3                 |
| 49–56      | 3.5               |
| 57–63      | 4                 |
| 64–71      | 4.5               |
| 72–79      | 5                 |
| 80–87      | 5.5               |

Table 6. Theoretically determined doses based on the weight of the child using tablet halves as the standard minimum tablet fraction and resulting in doses that are never below 40 mg/kg

| Weight (kg) | Number of tablets | Max. dose (mg/kg) |
|------------|-------------------|-------------------|
| 12–15      | 1                 | 50.0              |
| 16–22      | 1.5               | 56.3              |
| 23–30      | 2                 | 52.2              |
| 31–37      | 2.5               | 48.4              |
| 38–45      | 3                 | 47.4              |
| 46–52      | 3.5               | 45.6              |
| 53–60      | 4                 | 45.3              |
| 61–67      | 4.5               | 44.3              |
| 68–75      | 5                 | 44.1              |
| 76–82      | 5.5               | 43.4              |
| 83–90      | 6                 | 43.4              |

From a weighing scale to a pole
3.7% [2.8–4.8], of the children would have been given >15 or <15 mg by the dose-pole compared to the weight approach. Assuming that our findings are representative for Tanzania, and that half of the children between 5 and 15 years of age would receive praziquantel in a mass treatment campaign, approximately 200,000–330,000 children would have received a dose dissimilar from the ‘gold standard’. The largest deviations from the recommended dose occur on the higher side of the dose scale.

According to Hall et al. (4), the dose-pole would be good enough for a majority of schoolchildren, but the association between weight and height could get more complicated in endemic child populations where you might find malnutrition (15). There are, however, possibilities for improving the dose-pole. For some child populations, a mass treatment strategy, where extra concessions are made for those children who are lean or heavy for their height, might be preferable.

Follow-up studies concerning optimal dosage, side effects and effectiveness of praziquantel in mass treatment programs using the dose-pole seem to be nonexistent. According to WHO, the dose-pole delivers at least 40 mg/kg (1), which is not correct. What is needed to efficiently eradicate or at least reduce the number of parasites for different categories of individuals and yet minimize the possibility for the development of resistance, is not clear. Montresor (16) argues that the cure rate is not valid as an indicator for assessing drug efficacy and impact of preventive chemotherapy against schistosomiasis. This seems reasonable if the possibility of resistance development is not associated with the dosage.

There have been proposals to include even smaller children than currently recommended in mass treatment programs (13, 17). The idea is to include children from 60 cm of height in two new height intervals at the lower end of the dose-pole. As seen in our findings, it is exactly in this range of the height scale that the largest risk for deviations in dosage exists. The proposed extended dose-pole is not designed to take this into account; the suggestion is to distribute ¼ of a tablet to children between 83 or 84 and 99 cm, thereby introducing the need to use segments smaller than half a tablet.

The current dose-pole does not provide doses with higher precision than half a tablet. When adopting this half tablet strategy in a weight approach, the scale used does not need to be precise to the kilogram. The scale only has to correctly identify every 6th kg, which should make the weighing process rather simple. Given a properly functioning scale, the more extreme misclassifications would then be greatly reduced. From a practical point of view, weighing scales have already been constructed to show the number of tablets instead of kg in analogy to the dose-pole. Such modified scales have been proved to be robust in field tests (18). The conclusion is that the requirements for such a weighing device are not as high as previously assumed.

If one accepts the deviations we have observed using the dose-pole, not seeing the other alternatives, one also has to acknowledge the potential risks with the method. Our results, however, show that there indeed exists an alternative which gives higher precision.

Conclusions and interpretation

The WHO dose-pole based on height for praziquantel dosing will deliver different doses for a given weight of a child since for each weight different lengths of children will always be a fact. Our study shows that children with the same weight could qualify for up to four different dose levels of praziquantel. The largest variation of doses based on the WHO dose-pole will be found in children below 20 kg of bodyweight. Using bodyweight and tablet halves as the smallest tablet division unit to determine the doses of praziquantel, one only has to identify every 6th kilogram of bodyweight; the doses will then vary a lot less than when using the WHO dose-pole.

Authors’ contributions

Literature research: Krantz, Nordin, Poggensee; Study concept and design: Krantz, Nordin; Acquisation of data: All authors; Organization of field work and logistics: All authors; Data entry: Krantz, Nordin, Poggensee; Study supervision: Krantz; Statistical analysis: Nordin; Interpretation of data: Krantz, Nordin, Poggensee; Writing of the manuscript: Krantz, Nordin; Critical revision of the manuscript for important intellectual content: All authors.

Acknowledgements

The authors wish to thank the team members from the Kilimanjaro Christian Medical Centre and the Kileo Dispensary for their dedicated participation in the project. We thank Public Health Nurse, Pilli Nyindo, for her excellent and sustained work in the field and laboratory. We are indebted to the teachers, the schoolchildren and the village authorities of Kileo and Kivulini for the participation in the study.

Conflict of interest and funding

The investigation received support from the Swedish International Development Cooperation Agency/Department for Research Cooperation (SAREC).

References

1. WHO (2006). Preventive chemotherapy in human helminthiasis. Geneva: World Health Organization.
2. Montresor A, Engels D, Chitsulo L, Bundy DA, Brooker S, Savioli L. Development and validation of a ‘tablet pole’ for the administration of praziquantel in sub-Saharan Africa. Trans R Soc Trop Med Hyg 2001; 95: 542–4.
3. Stothard JR, Sousa-Figueiredo JC, Betson M, Green HK, Seto EY, Garba A, et al. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology 2011; 138: 1593–606.

4. Hall A, Nokes C, Wen ST, Adjei S, Kihamia C, Mwanri L, et al. Alternatives to bodyweight for estimating the dose of praziquantel needed to treat schistosomiasis. Trans R Soc Trop Med Hyg 1999; 93: 653–8.

5. Hodges MH, Dada N, Warmsley A, Paye J, Bangura MM, Nyorkor E, et al. Mass drug administration significantly reduces infection of *Schistosoma mansoni* and hookworm in school children in the national control program in Sierra Leone. BMC Infect Dis 2012; 12: 16.

6. French M, Churcher T, Gambhir M, Fenwick A, Webster JP, Kabaterine NB, et al. Observed reductions in *Schistosoma mansoni* transmission from large-scale administration of praziquantel in Uganda: a mathematical modelling study. PLoS Negl Trop Dis 2010; 4: e897.

7. Montresor A, Englés D, Ramsan M, Fourn A, Savioli L. Field test of the ‘dose pole’ for praziquantel in Zanzibar. Trans R Soc Trop Med Hyg 2002; 96: 323–4.

8. Montresor A, Odermatt P, Muth S, Iwata F, Raja’a YA, Assis AM, et al. The WHO dose pole for the administration of praziquantel is also accurate in non-African populations. Trans R Soc Trop Med Hyg 2005; 99: 78–81.

9. Geerts S, Gryseels B. Anthelmintic resistance in human helminths: a review. Trop Med Int Health 2001; 6: 915–21.

10. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009; 136: 1825–35.

11. Poggensee G, Krantz I, Nordin P, Mtweve S, Ahlberg B, Mosha G, et al. A six-year follow-up of schoolchildren for urinary and intestinal schistosomiasis and soil-transmitted helminthiasis in Northern Tanzania. Acta Trop 2005; 93: 131–40.

12. Bland JM, Altman DG. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 2003; 22: 85–93.

13. Sousa-Figueiredo JC, Pleasant J, Day M, Betson M, Rollinson D, Montresor A, et al. Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole. Int Health 2010; 2: 103–13.

14. National Bureau of Statistics (NBS) [Tanzania], ICF Macro (2011). Tanzania demographic and health survey 2010. Dar es Salaam, Tanzania: NBS.

15. Stephenson LS, Latham MC, Ottesen EA. Malnutrition and parasitic helminth infections. Parasitology 2000; 121: S23–38.

16. Montresor A. Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. Trans R Soc Trop Med Hyg 2011; 105: 361–3.

17. Sousa-Figueiredo JC, Betson M, Stothard JR. Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole. Int Health 2012; 4: 95–102.

18. Jack A, Bradley DJ. Scales modified for dose determination in population-based chemotherapy. Lancet 1991; 337: 219–21.